Mankind Pharma shares jump nearly 10% after strong second-quarter results
The Indian drugmaker's stock gained 9.3% as net profit rose 39% year on year. Brokerages remain split on the outlook, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Mankind Pharma shares rose 9.3% on Tuesday to Rs 2,527, extending a two-day rally. The gains followed results for the September quarter, when net profit climbed 39.2% to Rs 712 crore and revenue rose 17.3% to Rs 4,338 crore. EBITDA grew 27.1%, and exports jumped 32.7%, while domestic revenue increased 14.8%.
Brokerages disagree on the stock. Kotak Institutional Equities keeps a Buy rating with a target of Rs 3,035, JPMorgan and Macquarie take a cautious stance, and Bernstein rates the shares Underweight, citing valuation and an uneven recovery across therapy segments.
why it matters
The move came alongside a broader pharma rally, with the Nifty Pharma index up 1.7%, while the Nifty 50 has fallen 13.2% so far in 2026. Investors will watch whether the company can sustain strong domestic growth on a low base as consumer demand recovers.
market impact
Indian pharma: strong results lift Mankind Pharma shares and support the sector
- Mankind Pharma shares pressure up — strong quarterly results and profit growth attracted buyers
- Nifty Pharma index pressure up — the stock's rally lifted the broader Indian pharma sector
tags
instruments
sources
- Mankind Pharma stock surges 9% after strong Q2 results; Kotak sees big upside, other brokerages cautious — TradingView, 27 October 2026 at 08:45 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗